UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------------------------------------------------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
NEUROCRINE BIOSCIENCES, INC.
(Name of Issuer)
Common Stock, No Par Value
(Title of Class of Securities)
64125C109
(CUSIP Number)
Wayne P. Merkelson
Novartis Corporation
556 Morris Avenue
Summit, NJ 07901-1398
Telephone: (908) 277-2502
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and
Communications)
Copy to:
David W. Heleniak
Shearman & Sterling
599 Lexington Avenue
New York, New York 10022
Telephone: (212) 848-4000
May 9, 1997
(Date of Event which Requires Filing of this Statement)
-------------------------------------------------------------------------------
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|.
<PAGE>
CUSIP No. 64125C109
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Novartis AG
-----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of Group (See Instructions)
|_| (a)
--------------------------------------------------------------------
|_| (b)
--------------------------------------------------------------------
(3) SEC Use Only
-----------------------------------------------------------
--------------------------------------------------------------------
(4) Sources of Funds (See Instructions) OO
-----------------------------------
--------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items
2(d) or 2(e).
--------------------------------------------------------------------
(6) Citizenship or Place of Organization Switzerland
---------------------------------
Number of (7) Sole Voting Power 1,121,353
Shares -----------------------------------
Beneficially (8) Shared Voting Power 342,559
Owned by ---------------------------------
Each (9) Sole Dispositive Power 1,121,353
Reporting ----------------------------
Person (10) Shared Dispositive Power 342,559
With ----------------------------
- ---- -----------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person 1,463,912
----------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
-----------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
8.6%
-----------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions) CO
---------------------------
<PAGE>
CUSIP No. 64125C109
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Novartis Pharmaceuticals Corporation
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of Group (See Instructions)
|_| (a)
--------------------------------------------------------------------
|_| (b)
--------------------------------------------------------------------
(3) SEC Use Only
-----------------------------------------------------------
--------------------------------------------------------------------
(4) Sources of Funds (See Instructions) OO
-----------------------------------
--------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items
2(d)or 2(e).
--------------------------------------------------------------------
(6) Citizenship or Place of Organization Delaware
---------------------------------
Number of (7) Sole Voting Power -0-
Shares -----------------------------------
Beneficially (8) Shared Voting Power 342,559
Owned by ---------------------------------
Each (9) Sole Dispositive Power -0-
Reporting ----------------------------
Person (10) Shared Dispositive Power 342,559
With ----------------------------
- ---- -----------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person 1,463,912
-----------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
--------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
8.6%
--------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions) CO
---------------------------
<PAGE>
CUSIP NO. 64125C109 SCHEDULE 13D
Item 1. Security and Issuer
This Amendment No. 1 amends the Statement on Schedule 13D (the
"Schedule 13D") filed with the Securities and Exchange Commission on June 10,
1996 by Ciba-Geigy Limited. This Amendment No. 1 to Schedule 13D relates to
shares of common stock, no par value (the "Common Stock"), of Neurocrine
Biosciences, Inc. (the "Issuer"). The principal executive office and mailing
address of the Issuer is 3050 Science Park Road, San Diego, California 92121.
The following amendments to Items 1, 2, 3 and 5 and Schedules I and II of the
Schedule 13D are hereby made. Unless otherwise defined herein, all capitalized
terms shall have the meanings ascribed to them in the Schedule 13D.
Item 2. Identity and Background.
Item 2 of the Schedule 13D is amended as follows:
Novartis AG ("Novartis") is the successor by merger to
Ciba-Geigy Limited resulting from the merger of Sandoz Ltd. and Ciba-Geigy
Limited into Novartis on December 20, 1996. The principal offices of Novartis
are located at Schwarzwaldallee 215, CH-4002, Basel, Switzerland. The principal
business of Novartis is Life Sciences, which includes pharmaceuticals, consumer
health and vision care products, agribusiness (including crop protection, animal
health and seeds) and nutrition products.
Novartis Pharmaceuticals Corporation is an indirect wholly
owned subsidiary of Novartis. The principal offices of Novartis Pharmaceuticals
Corporation are located at 59 Route 10, East Hanover, New Jersey 07936. The
principal business of Novartis Pharmaceuticals Corporation is the development,
marketing and sales of pharmaceutical products.
Neither Novartis nor, to the best knowledge of Novartis, any
of the persons listed on Schedule I or Schedule II hereto during the past five
years has been convicted of any criminal proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgement, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to federal or
state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or other Consideration.
On May 9, 1997, as part of a distribution from Avalon Medical
Partners, Novartis Pharmaceuticals Corporation received 342,559 shares of Common
Stock of the Issuer. Avalon Medical Partners is an investment partnership in
which Novartis Pharmaceuticals Corporation had a 50% interest.
<PAGE>
CUSIP NO. 64125C109 SCHEDULE 13D
Item 5. Interest in Securities of the Issuer.
(a) Novartis beneficially owns 1,121,353 shares of Common
Stock and Novartis Pharmaceuticals Corporation owns 342,559 shares of Common
Stock. Together the shares of Common Stock held by Novartis and Novartis
Pharmaceuticals Corporation constitute approximately 8.6% of the outstanding
Common Stock of the Issuer.
(b) Novartis has sole power to vote and dispose of 1,121,353
shares of Common Stock owned by it. Novartis and Novartis Pharmaceuticals
Corporation share power to vote and dispose of 342,559 shares of Common Stock.
(c) Neither Novartis, Novartis Pharmaceuticals Corporation,
nor, to the best knowledge of Novartis and Novartis Pharmaceuticals Corporation,
any of the persons listed on Schedules I and II hereto, has effected any
transaction in the Common Stock in the past 60 days.
(d) No person other than the record owners referred to herein
is known to have the right to receive or the power to direct the receipt of
dividends from or proceeds of the sale of shares of Common Stock.
(e) Not applicable.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 21, 1998 NOVARTIS AG
By /s/ Urs Barlocher
---------------------------------
Name: Urs Barlocher
Title: General Counsel
By /s/ Christoph Maeder
---------------------------------
Name: Christoph Maeder
Title: Senior Corporate Counsel
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
NOVARTIS PHARMACEUTICALS
CORPORATION
By /s/ Kenneth Schuster
---------------------------------
Name: Kenneth Schuster
Title: Vice President & Controller
<PAGE>
SCHEDULE I
Members of the Board of Directors, the Committee of the Board
of Directors and the Executive Committee of Novartis AG.
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Dr. Alex Krauer Switzerland Chairman of the Board of Novartis AG
Novartis AG 1956 - Present: Novartis AG
CH-4002 Basle (formerly Ciba-Geigy Ltd.)
Switzerland
Dr. Daniel Lucius Vassella Switzerland President and Chief Executive
Novartis AG Officer of Novartis AG
CH-4002 Basel 1988 - 1996: Various functions at
Switzerland Sandoz AG
Hans-Joerg Rudloff Germany Vice Chairman of Novartis AG
McCook & Cie 1980 - 1994: Banker at Credit Suisse
1st Floor First Boston
7 Rue de Alpes 1994 - Present: MC-BBC Group
1201 Geneva
Switzerland
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Prof. Dr. Helmut Sihler Austria Vice Chairman of Novartis AG
c/o Henkel KGaA Currently Retired.
D. 40191 Dusseldorf June 1985-1993: Member of
Germany the Supervisory Board, Adam Opel AG
Since 1983: Member of the Supervisory
Board of Allianz Lebensversicherungs-AG
April 1991 - Present: Chairman of
the Supervisory Board Degussa AG
1995-1996: Chairman of the Supervisory
Board of Deutsche Post AG
1996 - Present: Chairman of the
Supervisory Board of Deutsche
Telekom AG
1991-1995: Member of the Shareholder's
Committee of Freudenberg & Co.
1992-1997: Member of the Board of Directors
of Guiness PLC
Since 1992: Member of the Shareholder's
Committee of Henkel KGaA
1992-1996: Chairman of the Supervisory
Board of Infratest Burke AG
1992-1997: Member of the Supervisory
Board of Leipziger Messe GmbH
Since March 1993: Chairman of the
Supervisory Board of Dr. Ing.
h.c.F. Porsche AG
Prof. Dr. Duilio Arigoni Switzerland Member of the Board of Directors of
LOC ETH-Z Universitat Str. 16 Novartis AG
Zurich CH-8002 1961 - Present: Professor of
Switzerland Chemistry at ETH Zurich
Birgit Breuel Germany Member of the Board of Directors of
c/o Expo 2000 Hannover GmbH Novartis AG
Thurnithistr 2 1995-Present: Commissioner General
30519 Hannover of Expo 2000
Germany 1991-1994: President of
Treuhandanstalt
Prof. Dr. Peter Burckhardt Switzerland Member of the Board of Directors of
University Hospital-CHUV Novartis AG
1011 Lausanne 1981 - Present: Chief of Medicine and
Switzerland Professor at CHUV
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Dr. h.c. Kaspar Cassani Switzerland Member of the Board of Directors of
Haldenstr. 53 Novartis AG
8142 Uitikon Retired since 1989
Switzerland
Dr. Hans-Ulrich Dorig Switzerland Member of the Board of Directors of
Credit Suisse First Boston Novartis AG
P.O. Box 900 Jan 1997-Present: Chief Executive
CH-8070 Zurich Officer of Credit Suisse First Boston
Switzerland 1973 - 1997: Banker at Credit Suisse
First Boston (formerly CreditSuisse)
Walter G. Frehner Switzerland Member of the Board of Directors of
Inzlingerstrasse 276 Novartis AG
CH-4125 Riehen Retired since 1996
Until 1996: Banker at Swiss Bank
Corporation
Robert L. Genillard Switzerland Member of the Board of Directors of
1, quai du Mont-Blanc Novartis AG
CH-1211 Geneva 1 1992 - Present: Corporate director of
Switzerland Clariden Bank, Credit Suisse Group
and TBG Holdings NV
Alexandre F. Jetzer Switzerland Member of the Board of Directors of
Novartis AG Novartis AG
CH-4002 Basel 1995 - Jan 1996: Vice-Chairman and
Switzerland CEO of Sandoz Corp (New York)
and Chairman and CEO of Sandoz
Pharmaceuticals Corporation (East
Hanover, NJ)
1981 - 1995: Member of the Corporate
Executive Committee of Sandoz AG
Pierre Landolt Switzerland Member of the Board of Directors of
Fazenda Tamandra Novartis AG
Patos-PB 58700-970 Since 1997: Chairman of Banco Axial S.A.
Brazil Since 1995: Chairman of Citco
Since 1994: General Manager of Sandoz
Family Foundation
Heini Lippuner Switzerland Member of the Board of Directors of
Novartis AG Novartis AG
CH-4002 Basel Until April 1996: President and COO
Switzerland of Ciba-Geigy AG
Prof. Dr. William J. Rutter United States Member of the Board of Directors of
Chiron Corporation Novartis AG
4560 Horton Street 1981 - Present: Chairman of Chiron
Emeryville, CA 94608 Corporation
Director of Novartis AG
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Dr. Jean Wander Switzerland Member of the Board of Directors of
Bollwerk 21 Novartis AG
P.O. Box 1037 Since 1985: Tax and Legal Counsel
CH-3001 Bern 1981 - Present: Director of Berner
Switzerland Tagblatt Medien AG
Dr. Raymund Breu Switzerland 1993 - Present: Chief Financial
Novartis AG Officer of Novartis AG (formerly
CH-4002 Basel Sandoz AG)
Switzerland
Dr. Hans Kindler Switzerland 1992- Present: Member of the Executive
Novartis AG Committee of Novartis AG (formerly
CH-4002 Basel Ciba-Geigy AG)
Switzerland
Pierre E. Douaze France 1992-1997: Member of the Executive
Novartis Committee and Head of Healthcare
CH-4002 Basel Division and Pharma Sector of
Switzerland Novartis AG (formerly Ciba-Geigy AG)
Dr. Wolfgang Samo Switzerland 1992 - Present: Head of Agribusiness
Novartis AG Novartis AG (formerly Ciba-Geigy
CH-4002 Basel AG)
Switzerland
David E. Pyott England 1995 - Dec 1997: Head of Nutrition
Novartis AG Division of Novartis AG (formerly
CH-4002 Basel Sandoz AG)
Switzerland
</TABLE>
<PAGE>
SCHEDULE II
Members of the Board of Directors and the Executive Committee of Novartis
Pharmaceuticals Corporation.
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Pierre E. Douaze France Chairman of the Board of Directors of
Novartis Pharma AG Novartis Pharmaceuticals Corporation
Lichtstrasse 35 1992-1997: Member of the Executive
CH-4002 Basel Committee and Head of Healthcare
Switzerland Division and Pharma Sector of
Novartis AG (formerly Ciba-Geigy AG)
Douglas G. Watson United States Vice Chairman of the Board of
Novartis Corporation Directors of Novartis
564 Morris Avenue Pharmaceuticals Corporation
Summit, NJ 07901 1996-Present: CEO of Novartis
Corporation (formerly Ciba-Geigy
Corporation)
Dr. Raymund Breu Switzerland Member of the Board of Directors of
Novartis AG Novartis Pharmaceuticals Corporation
CH-4002 Basel 1993-Present: Chief Financial Officer
Switzerland of Novartis AG (formerly Sandoz AG)
Dr. Claude A. Dulex Switzerland Member of the Board of Directors of
Novartis Finance Corp. Novartis Pharmaceuticals Corporation
608 Fifth Avenue 1996-Present: Chief Financial Officer
New York, NY 10020 of Novartis Finance Corporation
1990-1996: Chief Financial Officer of
Siegfried AG
Dr. Paul L. Herrling Switzerland Member of the Board of Directors of
Novartis Pharma AG Novartis Pharmaceuticals Corporation
CH-4002 Basel 1995-Present: Head of Global
Switzerland Research Novartis Pharma Research
(formerly Sandoz Pharma)
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Wayne P. Yetter United States President and CEO and Member of the
Novartis Pharmaceuticals Corporation Board of Directors of Novartis
59 Route 10 Pharmaceuticals Corporation
East Hanover, NJ 07936 1977-1996: Various positions at Astra
Merck Inc.
John Symon Australia Member of the Board of Directors of Novartis
Novartis Pharma AG Pharmaceuticals Corporation
CH-4002 Basel 1997 - Present: Head of Finance and
Switzerland I.T. of Novartis Pharma AG
1992-1997: Sandoz (India) Limited
Atef Adley Canada Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
59 Route 10 1995-1996: Head of Technical
East Hanover, NJ 07936 Operations International at
Ciba-Geigy Limited
1984-1995: Vice President at
Ciba-Geigy Canada Ltd.
George Beagley Canada Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
59 Route 10 1979-1996: Vice President of
East Hanover, NJ 07936 Ciba-Geigy
David Epstein United States Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals
59 Route 10 1989-1996: General Manager at
East Hanover, NJ 07936 Sandoz Pharmaceuticals Corporation
Daniel O. Hauser Switzerland Senior Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
59 Route 10 1992-1996: Senior Vice President of
East Hanover, NJ 07936 Sandoz Pharmaceuticals Corporation
Edward F. Heimers, Jr. United States 1987-Present: Senior Vice President of
Novartis Pharmaceuticals Corporation Novartis Pharmaceuticals
59 Route 10 Corporation (formerly Sandoz
East Hanover, NJ 07936 Pharmaceuticals Corporation)
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
Name and Business Address Citizenship Principal Occupation
- ------------------------- ----------- --------------------
<S> <C> <C>
Cynthia Hogan United States Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
59 Route 10 1985-1996: Vice President and
East Hanover, NJ 07936 Member of the Executive
Committee of Sandoz
Pharmaceuticals
Carolyn Koestenblatt United States Senior Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
59 Route 10 1975-1995: Various functions at
East Hanover, NJ 07936 Ciba-Geigy Corporation
Alan J. Main United Kingdom Senior Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
556 Morris Avenue 1992-1996: Senior Vice President of
Summit, NJ 07901 Ciba-Geigy Corporation
1982-1992: Scientist at Ciba-Geigy
Corporation
Urs A. Naegelin Switzerland Senior Vice President and
Novartis Pharmaceuticals Corporation Chief Financial Officer of
59 Route 10 Novartis Pharmaceuticals
East Hanover, NJ 07936 Corporation
1974-1996: Various positions at
Sandoz Pharmaceuticals Corp.
Eric Talbott United States Vice President of Novartis
Novartis Pharmaceuticals Corporation Pharmaceuticals Corporation
59 Route 10 March 1997-June 1997: Vice President
East Hanover, NJ 07936 of Med 3000
Dorothy Watson United States Vice President and General Counsel at
Novartis Pharmaceuticals Corporation Novartis Pharmaceuticals
59 Route 10 Corporation
East Hanover, NJ 07936 1992-1996: Deputy Counsel at
Ciba-Geigy
</TABLE>
